Sl.No. Vaccine Name Manufacturer Name Type of Vaccine Mechanism of Action Efficiency Reference
CoronaVac
Sinovac
Inactivated
Copies of killed COVID-19 viruses are administered. The individual’s immune system recognizes these inactivated viral particles as foreign antigens and initiates an immune response against it.
51% efficacy against symptomatic SARS-CoV-2 infection, 100% efficacy against severe COVID-19, and 100% efficacy against hospitalization starting 14 days after receiving the second dose
Covilo
Sinopharm (Beijing)
Efficacy of 79% against symptomatic SARS-CoV-2 infection 14 days after the second dose
Covaxin or BBV152
Bharat Biotech
Efficacy of 78% 14 days post dose 2; 93% efficacy against severe disease
Covishield
Serum Institute of India
Non replicating viral vector
The SARS-CoV-2 genetic material is packaged inside another harmless virus that cannot copy itself, and this preparation is administered as the vaccine
76% post 15 days after 2nd dose
Vaxzevria
Oxford/AstraZeneca
91.4% efficacy against hospitalization, 91.1% efficiency against ICU admissions, and 92.3% against the death
Ad26.COV2.S
Janssen (Johnson & Johnson)
efficacy of 85.4% against critical illness and 93.1 % against hospitalization after 28 days post-inoculation
Comirnaty or Tozinameran or BNT162b2
Pfizer/BioNTech
RNA vaccine
The SARS-CoV-2 genetic material (RNA encoding viral spike protein in this case) is administered as the vaccine, which is utilized by the cells to synthesize viral proteins. Antibodies are then generated against these viral proteins.
95% efficacy after 2 doses of administration
Spikevax or mRNA-1273
Moderna
Shows 94.1% efficacy
COVOVAX
Serum Institute of India
Protein subunit
Isolated and purified viral proteins alone are administered as the vaccine and antibodies are produced against these viral proteins.
More than 90% efficacy
Nuvaxovid or NVX-CoV2373
Novavax
90% efficacy against mild, moderate and severe disease.